MedArrive, a startup seeking to bridge the gap between telehealth and in-person care, launched last week on the back of $4.5 million in seed funding. Kleiner Perkins and Define Ventures co-led the round.
The startup employs and coordinates EMS providers who are deployed to the home of a patient. There, they can conduct basic clinical services and loop in the patient's physician virtually if additional oversight is needed during the encounter.
The company said that it plans to keep building out its tech platform, expand its team and target partnerships that will help push beyond its initial focus on the Florida market.
"Now more than ever, as we continue battling a global pandemic, patients deserve healthcare that is accessible, affordable, and safe,” Dan Trigub, cofounder and CEO of MedArrive, said in a statement.
“The current pandemic has placed additional stress on our already flawed health system – patients are avoiding clinics, delaying preventative and critical care, and facing financial strain. By working alongside communities of EMS professionals, providers and payors to bring high quality care into the home at a fraction of the cost of alternatives, MedArrive’s integrated solution is putting patients back at the center of care.”
Folx, a consumer-facing virtual health services program designed for the U.S. LGBTQIA+ population, has picked up $4.4 million in seed funding from Define Ventures, Bessemer Venture Partners and Polaris Partners, Crunchbase News reports.
The startup has so far staffed 12 queer and trans clinicians who provide customers with care ranging from hormone-replacement-therapy support, to pre-exposure prophylaxis, to home STI testing, with plans starting at $59 per month, according to the company's website. The company will be directing its new funds toward developing more treatment offerings, expanding its clinical network and entering new states.
Stanford University spinout Deepcell, which uses artificial intelligence for cell classification and isolation for cell biology and translational research, landed $20 million in Series A funding. Bow Capital led the round, with Andreesen Horowitz participating.
The company plans to use the new funding to build out a cell morphology atlas and propel its efforts in cell classification and sorting.
“From its early days in my lab to its launch as a startup, the Deepcell technology has offered the exciting potential of characterizing, identifying, and sorting cells without perturbation,” said Euan Ashley, professor at Stanford and cofounder of Deepcell. “Identifying and isolating cells on a spectrum, all the way down to ultra rare, harbors unprecedented potential for understanding single-cell biology and for advancing precision medicine.”
Insuretech company Centivo scored $34 million in Series B funding. The round was led by B Capital Group with participation from Define Ventures; HarbourVest Partners; Nassau Street Ventures, an AVG fund; Bain Capital Ventures; Company Ventures; F-Prime Capital, Ingleside Investors; Maverick Ventures; and Rand Capital.
The company is focused on the self-funded employer market. Members can access healthcare through a primary care-centered model, with fully integrated virtual care as well. The health plan aims to incentivize members to seek appropriate, cost-effective care and maintain adherence to their personal care plans.
The company plans to use the new money to expand its offerings and scale its operation.